Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact
Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact

124I-evuzamitide PET/MR Unveils Hypertrophic Cardiomyopathy in a Patient with Renal AL Amyloidosis

Sep 30, 2023 Posters & Publications

AUTHORS: Jessica Cardin, Derrick Gillan, Adam Brown, Nadine Mallak, Eva Medvedova, Ahmad MasriOHSU Oregon Health & Science University Click Here to View...

I-124 Evuzamitide PET/CT is More Sensitive than Tc-99m Pyrophosphate forthe Diagnosis of Hereditary Transthyretin Cardiac Amyloidosis

Sep 30, 2023 Posters & Publications

AUTHORS: Dia A. Smiley1, DO, Andrew J. Einstein1,2, MD, PhD, Denisse Santana Del Rosario1, MD, Nicholas Chan1, MD, Akiva Mintz2, MD, PhD, Kim Goldner2, CNMT,RT, Stephen T. Helmke1 RDCS, MPH, Margaret O. Cuomo1, NP, Ani Nalbandian1, MD, Sergio Teruya1, MD, Samantha...

I-124 Evuzamitide PET/CT is More Sensitive than Tc-99m Pyrophosphate for the Diagnosis of Hereditary Transthyretin Cardiac Amyloidosis

Sep 30, 2023 Posters & Publications

AUTHORS: Dia Smiley, Andrew Einstein, Denisse Santana, Nicholas Chan, Akiva Mintz, Kimberly Goldner, Stephen Helmke, Margaret Cuomo, Ani Nalbandian, Sergio Teruya, Samantha Guadalupe, Jeffeny De Los Santos, Alfonsina Mirabel, Mary Paulino, Kimberly Collado, Carlos...
Next Entries »

Recent Posts

  • Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis
  • Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus
  • Renal and cardiac responses in a phase 1/2 study of AT-02, a novel pan-amyloid depleter IgG fusion protein for the treatment of patients with AL amyloidosis
  • Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
  • Accurate Quantitation of Cardiac Amyloidosis by 124I-Evuzamitide Compared to Extracellular Volume

Recent Comments

No comments to show.
COMPANY
About
Management Team
Board of Directors
Scientific Advisory Board
Investors

SCIENCE
Approach
PAR Therapeutics

PIPELINE

NEWS
Press Releases
Posters & Publications

AMYLOIDOSIS
CAREERS
CONTACT

  • Privacy Policy
  • Terms of Service
  • Follow
  • Follow
Attralus logo

Attralus, Inc.
365 Fifth Ave South, Ste 208
Naples, FL 34102

©2026 Attralus, Inc.  All Rights Reserved.